Supplementary Data from Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis by Highly Expressing and Secreting SEMA4C
Jun-Cheng Wei,Jie Yang,Dan Liu,Ming-Fu Wu,Long Qiao,Jun-Nai Wang,Quan-Fu Ma,Zhen Zeng,Shuang-Mei Ye,En-Song Guo,Xue-Feng Jiang,Lan-Ying You,Ying Chen,Li Zhou,Xiao-Yuan Huang,Tao Zhu,Li Meng,Jian-Feng Zhou,Zuo-Hua Feng,Ding Ma,Qing-Lei Gao
DOI: https://doi.org/10.1158/1078-0432.22466258.v1
2023-01-01
Abstract:The "Supplemental Data" contains supplementary methods,supplementary table 1 and supplementary figures1-19.1.Supplementary methods: Antibodies and Reagents, Primary culture of LECs, Immunomagnetic isolation of LECs, Expressing human recombinant sSEMA4C protein, Liquid chromatography - Electrospray ionization tandem MS (LC-ESI/MS), Migration assay, Wound healing assay, Cell proliferation assay, Primers sequences; 2.Supplementary Table 1: the Patient characteristics; 3.Supplementary Figure 1: the Authentication of LECs; 4.Supplementary Figure 2: the Evaluation of LCM-isolated LECs using RNA markers; 5. Supplementary Figure 3 : SEMA4C expresses on lymphatic vessels; 6.Supplementary Figure 4 : Nano-LC-ESI-MS/MS spectrum of a single charged deglycosylated glycopeptide from the culture supernatants of tumor LECs; 7. Supplementary Figure 5 :sSEMA4C binds to tumor cells and LECs; 8.Supplementary Figure 6: sSEMA4C promotes the migration and proliferation of tumor cells; 9.Supplementary Figure 7: SEMA4C promotes LECs function in vitro; 10.Supplementary Figure 8 : targeting SEMA4C inhibits LECs function in vitro; 11.Supplementary Figure 9 : the growth of the tumors; 12.Supplementary Figure 10 : Knock-down of PlexinBs; 13.Supplementary Figure 11 : Blocking ERBB2 or PlexinB2 inhibits SEMA4C-induced lymphangiogenesis in vitro; 14.Supplementary Figure 12 : LEC was stimulated by VEGF-C and sSEMA4C; 15.Supplementary Figure 13 : sSEMA4C activates MET and RHOA in tumor cells; 16.Supplementary Figure 14 : blocking MET or PlexinB2 inhibits SEMA4C-induced migration and proliferation of tumor cells; 17.Supplementary Figure 15 : cells treated with sSEMA4C; 18.Supplementary Figure 16 : targeting RHOA inhibits SEMA4C-induced lymphangiogenesis in vitro and in vivo; 19.Supplementary Figure 17 : targeting RHOA inhibits SEMA4C-induced migration of tumor cells; 20.Supplementary Figure 18 : 3 days after inoculation with tumour cells, the mice were treated with Lapatinib, K252a ,C3 toxin, Fasudil, Y27632 , sSEMA4C and PBS control solution, the size of tumor was measured; 21.Supplementary Figure 19: 3 days after inoculation with tumour cells, the mice were treated with Lapatinib, K252a ,C3 toxin, Fasudil, Y27632 , sSEMA4C and PBS control solution, the average number of positive lymph node in each mice were calculated.